Ben Kong

Ben Kong

University of Sydney - Sydney / Australia
Medical and Health Sciences / Immunology
AD Scientific Index ID: 41870
person_outline Ben Kong's MOST POPULAR ARTICLES
1-) Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapyJ Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...Journal of Clinical Oncology 35 (7), 709, 20178402017
2-) High response rate to PD-1 blockade in desmoplastic melanomasZ Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ...Nature 553 (7688), 347-350, 20182942018
3-) Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortSJE Hwang, G Carlos, D Wakade, K Byth, BY Kong, S Chou, MS Carlino, ...Journal of the American Academy of Dermatology 74 (3), 455-461. e1, 20162912016
4-) Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialGV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ...The Lancet Oncology 18 (9), 1202-1210, 20172922017
5-) Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanomaRE Vilain, AM Menzies, JS Wilmott, H Kakavand, J Madore, A Guminski, ...Clinical Cancer Research 23 (17), 5024-5033, 20172602017